Compare Hims and Hers Health Inc (HIMS) vs Nutrien Ltd (NTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Nutrien Ltd — how do they compare? Hims and Hers Health Inc trades at $32.39 (market cap $7.57B), while Nutrien Ltd trades at $66.94 (market cap $31.67B). The key difference: Nutrien Ltd is far larger — about 4.2× Hims and Hers Health Inc's market cap, and Nutrien Ltd pays a 3.3% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals.
| HIMS | NTR | |
|---|---|---|
Market Cap | $7.57B | $31.67B |
Sector | Health | Basic Materials |
52-Week High | $66.18 | $83.94 |
52-Week Low | $14.52 | $53.64 |
Enterprise Value | $7.95B | $44.84B |
Dividend Yield | — | 3.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $32.70, down 0.43% on the day, with a bearish technical signal despite bullish moving averages. The company reported $2.35 billion in 2025 revenue but swung to a projected net loss for 2026, with mixed quarterly earnings results. Recent news highlights executive changes and anticipation for Q2 2026 results on August 10, 2026, with analyst sentiment leaning toward a Buy consensus.
The outlook is cautious due to profitability concerns and high valuation multiples, but growth opportunities in weight-loss and telehealth services offer potential. Key risks include execution challenges and regulatory scrutiny. The stock presents a speculative growth play with a consensus price target of $33.57, slightly above the current price.
Nutrien (NTR) trades at $66.40, down 1.31% on the day, with a bullish technical outlook supported by moving averages. The company shows improving fundamentals with Q1 2026 EPS beating expectations at $0.51 versus $0.48, and revenue trending upward to $26.89B in 2025. Valuation ratios appear attractive with a P/E of 13.7 and P/S of 1.17. Analyst sentiment is positive with a consensus price target of $77.67, representing 17% upside, and 61% of analysts rate it a Buy.
The outlook for Nutrien is favorable due to strong fertilizer demand and cost management, though risks include volatile input costs and competitive pressures. With solid cash flow from operations and a dividend payout, the stock offers value and income potential, but investors should monitor global agricultural trends and energy market impacts on margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
